SCHEMBL19852325

SCHEMBL19852325

Fc1ccc(OC2CCN(CCC3CCOc4ccccc43)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.53
HTR2A P28223 5/20 0.45
HTR7 P34969 3/20 0.45
ADRA1B P35368 2/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
DRD2 P14416 3/20 0.39
DRD3 P35462 3/20 0.39
ADRB2 P07550 1/20 0.39
HRH3 Q9Y5N1 1/20 0.37
SSTR5 P35346 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
DRD1 P21728 1/20 0.37
DRD4 P21917 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852330 0.90 HTR7 (0.45) KCNH2HTR2AHTR7ADRA1BCARM1
SCHEMBL19838628 0.89 HTR2A (0.41) KCNH2HTR2AHTR7CARM1PRMT6
Hydrochloric Acid SCHEMBL19838581 0.88 HTR2A (0.41) KCNH2HTR2AHTR7CARM1PRMT6
SCHEMBL19852411 0.88 KCNH2 (0.46) KCNH2HTR2AHTR7ADRA1B
SCHEMBL19852525 0.88 KCNH2 (0.46) KCNH2HTR2AHTR7ADRA1B
SCHEMBL21072473 0.81 HTR7 (0.42) HTR2AHTR7CARM1PRMT6ADRB2
SCHEMBL19838875 0.81 HTR7 (0.54) HTR2AHTR7ADRA1BCARM1PRMT6
Hydrochloric Acid SCHEMBL19838877 0.80 HTR7 (0.53) HTR2AHTR7ADRA1BCARM1PRMT6
Hydrochloric Acid SCHEMBL10407709 0.80 HTR1A (0.55) KCNH2HTR2AHTR7ADRA1BDRD2
Hydrochloric Acid SCHEMBL9785678 0.78 HTR2C (0.57) HTR2AHTR7DRD2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C KCNH2 158/4885HTR2A 2/4885HTR7 112/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C KCNH2 158/4885HTR2A 2/4885HTR7 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.